| Document |
Document Title |
|
WO/2018/049184A1 |
Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension may include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocoll...
|
|
WO/2018/043597A1 |
The development of novel agricultural/horticultural insecticides is desired due to damage by pests and the like continuing to be a major issue, the evolution of pests resistant to existing chemicals, and other such factors in crop produc...
|
|
WO/2018/043400A1 |
A compound represented by formula (I) or a salt thereof. In formula (I), each of R1 and R4 independently represents a hydrogen atom, an unsubstituted or substituted C1-6 alkyl group or the like; R2 represents a hydrogen atom, an unsubsti...
|
|
WO/2018/043675A1 |
The present invention addresses the problem of developing and providing a novel pesticide for agricultural and horticultural use for reasons such that there is still extensive damage on the production of agricultural and horticultural cr...
|
|
WO/2018/037386A1 |
A method for treating or preventing protozoan parasite infection comprising administering to a mammal in need thereof naltrexone or a pharmaceutically acceptable salt thereof alone or in combination with one or more anti-protozoal agents...
|
|
WO/2018/037343A1 |
The present technology relates to vaccine compositions for the treatment and/or prevention of visceral leishmaniasis in mammals, comprising six synthetic peptides that are free or expressed in the surface of non-infectious bacteriophages...
|
|
WO/2018/034227A1 |
Provided is an anti-LAG-3 antibody that can be frequently administered to a non-rat animal. The anti-LAG-3 antibody comprises: (a) an L chain comprising an L-chain variable region that includes CDR1 having a QSLLDSDGNTY (SEQ ID NO. 16) a...
|
|
WO/2018/027252A1 |
Disclosed are compounds for use in modulating immune responses. More particularly, the present invention discloses oligomeric forms of PD-L2 for use in modulating Th1 immune responses. The compounds of the present invention find utility ...
|
|
WO/2018/023182A1 |
The present invention discloses red propolis extract-loaded nanospheres (RPNs), composed of standardized hydroalcoholic extract of red propolis originating from red propolis in its natural form, and of polymeric matrices having a functio...
|
|
WO/2018/018121A1 |
The present invention relates to the composition comprising the peptide as defined in SEQ ID NO: 1, 3, 4 or 5 and a pharmaceutically acceptable carrier. The present invention further relates to the use of a peptide as defined in SEQ ID N...
|
|
WO/2018/023111A1 |
Provided herein are γδ T cell suppressors and methods of using such in detecting and treating solid tumors, as well as detection of solid tumors such as PDA or CRC based on the level of γδ T cells.
|
|
WO/2018/021400A1 |
The present invention relates to a medicine for treating cancer or an infectious disease, said medicine comprising a combination of an immune check point inhibitor with an adjuvant composition. More specifically, the present invention re...
|
|
WO/2018/015940A1 |
The present application relates to the use of bacterial CNF (Cytotoxic Necrotizing Factor) and/or DNT (dermonecrotic toxin) as active ingredients or active ingredient for the prevention and/or the treatment of malaria caused by Plasmodiu...
|
|
WO/2018/014473A1 |
Provided is a compound artesunate pharmaceutical composition for pet dogs and pet cats. The composition is prepared with the following raw materials (in parts by weight): artesunate (0.3-3), artemether (0.2-2), halofuginone extract (5-15...
|
|
WO/2018/010965A1 |
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related m...
|
|
WO/2018/008727A1 |
The present invention provides a heterocyclic compound that exhibits a superior control against harmful arthropods and that is represented by formula (I): (I) [in the formula, Q1 represents an oxygen atom or the like; Q2 represents an ox...
|
|
WO/2018/003924A1 |
Provided is a novel pest control agent, especially a bactericide or a nematicide. An alkynylpyridine-substituted amide compound represented by formula (I) or a salt thereof; and a pest control agent which contains the compound or the sal...
|
|
WO/2018/003976A1 |
In agricultural and horticultural crop production, etc., damage by pests and the like remains devastating even today, and due to factors such as the occurrence of pests resistant to existing chemicals, there is a demand for the developme...
|
|
WO/2017/220517A1 |
The invention relates to a compound of formula (I) wherein R1 to R4 and n are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2017/221158A1 |
The present invention relates to a nanoparticle composition comprising one or more β-triketones selected from leptospermone, isoleptospermone, grandiflorone and flavesone, together with a carrier.
|
|
WO/2017/222996A1 |
Provided herein are compounds, compositions and method of using thereof to treat or prevent malaria.
|
|
WO/2017/214683A1 |
The present invention provides a method for the treatment or prophylaxis of an ectoparasitic infestation, the method comprising the step of: contacting an external surface of an animal in need thereof with an effective amount of a berber...
|
|
WO/2017/211909A1 |
The invention concerns a lipid composition that is self-emulsifying in the presence of a hydrophilic phase, comprising between 0.001% and 20% by weight, relative to the total weight of the composition, of at least one active substance; b...
|
|
WO/2017/212239A1 |
The present invention provides a sulphur-containing compound for use in the prophylaxis or treatment of an infection associated with at least one microbe or microbial strain displaying at least some degree of drug resistance. Also provid...
|
|
WO/2017/214076A1 |
The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-i...
|
|
WO/2017/210262A1 |
The present invention targets the Zika virus and other disease-causing microbes including viruses, bacteria, fungi, and parasites. It does this using agents and methods with little toxicity compared to existing therapies.
|
|
WO/2017/205464A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2017/198178A1 |
A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula ...
|
|
WO/2017/195069A1 |
The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
|
|
WO/2017/195136A1 |
The invention relates to novel N-(α-peroxy)indole compounds of Formula I and methods for use. (I) The N-(α-peroxy)indole compounds described herein are useful for treating or preventing parasitic infections, bacterial infections, and c...
|
|
WO/2017/195138A1 |
The invention relates to novel N-(α-peroxy)carbazole compounds of Formula I and methods for use. (I) The N-(α-peroxy)carbazole compounds described herein are useful for treating or preventing parasitic infections, bacterial infections,...
|
|
WO/2017/193017A1 |
The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infe...
|
|
WO/2017/191138A1 |
Compositions and methods for treating and preventing crustacean ectoparasitesinfection of fish are disclosed herein.
|
|
WO/2017/192385A1 |
The present invention provides compounds of the formula : (I) wherein: X is O or S; Q1 and Q2 are independently CR5 or N, provided at least one of Q1 and Q2 is N; Y is a direct bond or CH2; R1 is H, optionally substituted alkyl, alkenyl,...
|
|
WO/2017/186182A1 |
Provided herein is a humanized anti-BASIGIN antibody or antigen binding fragment thereof, which comprises heavy chain variable region(V H) comprising an amino acid sequence of SEQ ID NO:1, optionally further comprises light chain variabl...
|
|
WO/2017/184456A1 |
Disclosed herein are polynucleotides encoding multi-epitope polypeptides and assemblies thereof, and their use for treating or limiting Toxoplasma gondii infection.
|
|
WO/2017/184537A1 |
Compositions suitable for topical use to treat ectoparasite infestations are described. The compositions are suitable for use on the hair of humans or animals, without the need for pharmaceuticals or medicaments. The compositions are ess...
|
|
WO/2017/178524A1 |
The present invention relates to a process for the preparation of pyrvinium pamoate, which comprises reacting pyrvinium methyl sulphate salt of formula (II) with disodium pamoate of formula (III), in the presence of a base; to processes ...
|
|
WO/2017/177433A1 |
The present invention provides a pharmaceutical composition for killing ectoparasites of animals. The pharmaceutical composition contains an active ingredient and monoester; the active ingredient comprises at least one of albendazole, am...
|
|
WO/2017/178416A1 |
The present invention covers Pyrazolopyrimidine compounds of general formula (I), in which n, o, X, Y, R, Q, R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said c...
|
|
WO/2017/137177A9 |
Provided are compositions for non-stressful activation of cellular, tissues specific and systemic immune defenses in the treatment of bacterial, virus, fungal or parasite (protozoa) infections and infections/inflammation arising from tox...
|
|
WO/2017/176762A1 |
The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles th...
|
|
WO/2017/173956A1 |
A compound represented by formula (I) for preventing and treating human or animal parasitic infection, wherein the R group is either a -CH3 or -C2H5 group; the R group is -CH3 in tenvermectin A and is -C2H5 in tenvermectin B. Both of the...
|
|
WO/2017/176948A1 |
This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine- based chiral phase transfer catalysts. The invention also relates to novel quinine-based phase transf...
|
|
WO/2017/174620A1 |
The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
|
|
WO/2017/168476A1 |
An object of the present invention is to provide a novel anti-Tritrichomonas agent. Provided is an anti-Tritrichomonas agent containing luliconazole.
|
|
WO/2017/173049A1 |
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
|
|
WO/2017/173048A1 |
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin- related disorders.
|
|
WO/2017/173052A1 |
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.
|
|
WO/2017/170712A1 |
The present invention addresses the problem of providing a chemosynthetic adjuvant for selectively inducing TSLP. The present invention provides a vaccine adjuvant including a RAR γ agonist, and a vaccine obtained by combining the vacci...
|
